anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
BACKGROUND: Redox signaling caused by knockdown (KD) of Glutathione Peroxidase 2 (GPx2) in the PyMT mammary tumour model promotes metastasis via phenotypic and metabolic reprogramming. However, the tumour cell subpopulations and transcriptional regulators governing these processes remained unknown.
METHODS: We used single-cell transcriptomics to decipher the tumour cell subpopulations stimulated by GPx2 KD in the PyMT mammary tumour and paired pulmonary metastases. We analyzed the EMT spectrum across the various tumour cell clusters using pseudotime trajectory analysis and elucidated the transcriptional and metabolic regulation of the hybrid EMT state.
RESULTS: Integration of single-cell transcriptomics between the PyMT/GPx2 KD primary tumour and paired lung metastases unraveled a basal/mesenchymal-like cluster and several luminal-like clusters spanning an EMT spectrum. Interestingly, the luminal clusters at the primary tumour gained mesenchymal gene expression, resulting in epithelial/mesenchymal subpopulations fueled by oxidative phosphorylation (OXPHOS) and glycolysis. By contrast, at distant metastasis, the basal/mesenchymal-like cluster gained luminal and mesenchymal gene expression, resulting in a hybrid subpopulation using OXPHOS, supporting adaptive plasticity. Furthermore, p63 was dramatically upregulated in all hybrid clusters, implying a role in regulating partial EMT and MET at primary and distant sites, respectively. Importantly, these effects were reversed by HIF1α loss or GPx2 gain of function, resulting in metastasis suppression.
CONCLUSIONS: Collectively, these results underscored a dramatic effect of redox signaling on p63 activation by HIF1α, underlying phenotypic and metabolic plasticity leading to mammary tumour metastasis.
The present invention relates to a traditional Chinese medicine for curing cough, cough with phlegm and cough with dyspnea which are caused by acute and chronic tracheitis, asthma, pulmonary heart diseases and other diseases, particularly a medicine for curing cough and asthma, which belongs to the medicine technical field. The present invention is characterized in that traditional Chinese medicine for curing cough and asthma is composed of the traditional Chinese medicine of tendrilleaf fritillary bulb, tabasheer, pinellia tuber, dried ginger, tatarian aster root, common coltsfoot flower, radix glycyrrhiza, camphor, cinnabar, ephedrae, semen lepidii, fennel, opium, diphenhydramine and sodium benzoate according to a proportion by weight; the Chinese herbal medicine is accurately weighed, selected, cleaned and respectively ground into fine powder, the ground superfine powder is uniformly mixed, sieved by a sieve with 120 meshes, sterilized and filled in a No. 1 capsules. The medicine for curing cough and asthma of the present invention is used for treating various cough and asthma symptoms, has the efficacy of phlegm elimination, cough relief and asthma relief and has special effect on acute and chronic tracheitis, bronchitis, emphysema, pulmonary heart diseases and cough with dyspnea. The present invention has the characteristics of short treatment courses, rapid effect taking and high curative rate. The observation statistic of the clinic curative effect of 256 cases of patients shows that the total effective rate can reach 98.44%, and the curative rate reaches 74.61%.
Techniques are described for component configuration based on sensor data. Sensor data is collected by sensors in, or proximal to, a system under diagnosis (e.g., a vehicle), the sensor data describing the use of component(s) of the system by individual(s). The sensor data is analyzed (e.g., in real time) to determine an updated configuration for component(s) (e.g., an adjustment to the seat back, lumbar support of a car seat, etc.). The updated configuration may be communicated to the individual as a recommended configuration. In some implementations, the updated configuration may be communicated directly to the component which, on receiving and processing the configuration update, sends signals to various actuators to move the subcomponents of the component into the updated configuration. In some implementations, the sensor data is used to train, through machine learning, a model that provides configuration update(s) for component(s) based on the input sensor data.
Retrospective case-control studies in patients of European, Korean, and Japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLA-A*3101, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine. These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms (see DRESS/Multiorgan hypersensitivity below).

HLA-A*3101 is expected to be carried by more than 15% of patients of Japanese, Native American, Southern Indian (for example, Tamil Nadu) and some Arabic ancestry; up to about 10% in patients of Han Chinese, Korean, European, Latin American, and other Indian ancestry; and up to about 5% in African-Americans and patients of Thai, Taiwanese, and Chinese (Hong Kong) ancestry.

The risks and benefits of carbamazepine therapy should be weighed before considering carbamazepine in patients known to be positive for HLA-A*3101.

Application of HLA genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive and HLA-A*3101-positive patients treated with carbamazepine will not develop SJS/TEN or other hypersensitivity reactions, and these reactions can still occur infrequently in HLA-B*1502-negative and HLA-A*3101-negative patients of any ethnicity. The role of other possible factors in the development of, and morbidity from, SJS/TEN and other hypersensitivity reactions, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring, have not been studied.
PURPOSE:To obtain a curing promoter for wounds, capable of promoting treatment of the wounds causing a rupture in the skin or mucous membrane, excellent in biocompatibility and having high safety. CONSTITUTION:The curing promoter for wounds contains acidic heteropolysaccharides extracellularly secreted by a callus induced from a plant which belongs to the genus Polianthes (e.g. Polianthes tuverosa L.) as an active ingredient. The acidic heteropolysaccharides contain arabinose, mannose, galactose, glucuronic acid and xylose as constituent saccharides and the binding manner and constituent ratio thereof are expressed by the formula. The acidic heteropolysaccharides have 1X10<4> to 2X10<7> molecular weight and physicochemical properties such as solubility: soluble in water and insoluble in ethanol, ether and acetone; color reaction: positive to the allethrone reaction and carbazole reaction and negative to the Elson-Morgan reaction and specific rotatory power: [alpha]<25>D=0 to +20 deg. (C=1.0, aqueous solution).
Peripheral artery disease (PAD) affects more than 230 million people worldwide, with approximately 11% of patients presenting with advanced-stage PAD or critical limb ischemia (CLI). To avoid or delay amputation, particularly in no-option CLI patients with infeasible or ineffective revascularization, new treatment strategies such as regenerative therapies should be developed. Mesenchymal stem cells (MSCs) are the most popular cell source in regenerative therapies. They possess significant characteristics such as angiogenic, anti-inflammatory, and immunomodulatory activities, which encourage their application in different diseases. This phase I clinical trial reports the safety, feasibility, and probable efficacy of the intramuscular administration of allogeneic Wharton's jelly-derived MSCs (WJ-MSCs) in type 2 diabetes patients with CLI. Out of six screened patients with CLI, five patients were administered WJ-MSCs into the gastrocnemius, soleus, and the proximal part of the tibialis anterior muscles of the ischemic lower limb. The safety of WJ-MSCs injection was considered a primary outcome. Secondary endpoints included wound healing, the presence of pulse at the disease site, the absence of amputation, and improvement in visual analogue scale (VAS), pain-free walking time, and foot and ankle disability index (FADI). No patient experienced adverse events and foot or even toe amputation during the 6-month follow-up. Six months after the intervention, there were a significantly lower VAS score and significantly higher pain-free walking time and FADI score than the baseline, but no statistically significant difference was seen between other time points. In conclusion, allogeneic WJ-MSC transplantation in patients with CLI seems to be safe and effective.
The invention discloses a Kazak pharmaceutical combination for treating kidney-qi-deficiency diabetes and a preparation method of the Kazak pharmaceutical combination. The Kazak pharmaceutical combination combines the six element theory namely the ozeg alta turor theory, the qi, function and energy theory namely the Huwati theory, the body fluid theory namely the Sule theory, the organ theory namely the muxielieer theory and the like of the traditional medicine theoretical basis Introduction to Kazakh Medical Science, and mainly aims at preventing and treating diabetes. The Kazakh traditional medicinal materials of root of straight ladybel, radix ophiopogonis, dried rehmannia root, radix paeoniae alba, scrophularia, fructus ligustri lucidi and yerbadetajo herb are selected to be subjected to water extraction and ethanol extraction, and then uniformly mixed to be prepared into a preparation for oral administration. The forms of the preparation comprise all forms of preparation for oral administration, such as decoction, pill, powder, granula and the like, which are suitable for clinically preventing and treating the diabetes. The Kazak pharmaceutical combination has a good curative effect especially for adjuvant therapy for oral administration for the kidney-qi-deficiency diabetes. The Kazak pharmaceutical combination has the advantages of reasonable formula, convenience in preparation, significant curative effect, and no toxic or side effect.
BACKGROUND: Only 1% of Americans eligible for metabolic and bariatric surgery (MBS) receive MBS. Prior studies have analyzed primary care provider (PCP) referral patterns and perceptions of MBS as a potential barrier to increasing MBS. However, less data exists regarding PCP knowledge of MBS indications and outcomes. Following the 2022 update to the indications for MBS by the ASMBS and IFSO, the number of eligible patients is only expected to increase. We evaluated PCP knowledge regarding the existence of the 2022 ASMBS and IFSO updated guidelines, MBS indications, and MBS outcomes.
METHODS: An 11-question survey was emailed to primary care residents, advanced practice providers, and faculty at a single institution.
RESULTS: Of 151 surveys distributed, 39.7% responded (n = 60). 95% were unaware of the 2022 updated guidelines. On multiple choice questions, 16.3% correctly identified the average weight loss from MBS, and 46.8% correctly answered the diabetes remission rate following MBS. Trainee answers were not statistically significant from practicing PCPs. Fifteen respondents had referred a patient for MBS, but this subgroup did not perform significantly better on the assessment. A total of 72.3% of respondents reported inadequate MBS education during their training, and 85.1% were interested in additional education.
CONCLUSIONS: We present the first assessment of PCP MBS knowledge since the release of the 2022 updated ASMBS and IFSO guidelines. This study indicates a gap in PCPs' knowledge regarding the updated guidelines and represents an opportunity for collaboration with our primary care colleagues to provide further MBS education.
Emerging evidence indicates that sites outside of blood plasma, such as peripheral blood mononuclear cells (PBMCs) and gut-associated lymphoid tissue, remain reservoirs for HIV and play critical roles in viral persistence despite long-term potent combination antiretroviral therapy (cART). Suboptimal ARV drug concentrations within these reservoirs are thought to contribute to our inability to fully eradicate HIV. In addition, host factors such as sex have been found to impact ARV drug exposure within these sites and effect key outcomes such as time to virologic suppression. The understanding of reservoir site pharmacology and the impact on sex is limited due to several barriers: 1) Difficulty in sampling reservoir sites intensively and 2) Scarcity of women enrolled in HIV clinical research studies. Optimal drug concentrations are ideally determined early in drug development by dose-ranging studies that require intensive blood plasma sampling; this methodology is impractical to employ within tissue sites. To mitigate these barriers, the researchers propose to study the pharmacology of the integrase strand transfer inhibitor dolutegravir (DTG) within three body compartments: blood plasma, PBMCs, and rectal tissue using a novel integrated population pharmacokinetic-viral dynamic (PK-VD) modeling approach. This PK-VD modeling strategy generates concentration-response relationships with limited sampling and dosing simulations ideally suited to reservoir sites.

The primary aim of this study is to validate the integrated population PK-VD model that quantitatively describes the relationship between dolutegravir (DTG) exposure and HIV viral decay in blood plasma. The second aim of this study is to develop an integrated population pharmacokinetic-viral dynamic (PK-VD) model to describe the relationship between DTG exposure and HIV viral decay in peripheral blood mononuclear cells and rectal tissue reservoir sites. The third aim is exploratory and will investigate sex differences in DTG penetration into blood plasma, peripheral blood mononuclear cells and rectal tissue reservoirs reservoirs as well as its impact on the rectal microbiome.
Postoperative pulmonary and musculoskeletal complications are the most frequent and significant contributor to morbidity, mortality with hospitalization. Pilates-based exercise has be applied to improve core control, movement efficiency and postural stability. High incidence of musculoskeletal problems have been concerned in relation to the patient's functional recovery after cardiac surgery. However, no literature is addressed how to manage this issue effectively till now. The purpose of this clinical trial is to evaluate the effect of pilates-based cardiopulmonary physical therapy for in-patients after cardiac surgery. This is a single-blinded, randomized control trial. Investigators will enroll pre-cardiac surgery and allocate subjects to modified Pilates-based training group or control group using block randomization.The training protocol will be based on pilates concepts. The control group is treated with a conventional protocol of physical therapy. The study will be carried on whole in-patient phase. During this period, patients received respiratory motion analysis, chest wall muscles mobility, lung function and endurance evaluation. Patients' changes in respiratory movement, cardiopulmonary endurance, and lung function will be evaluated by an assessor blinded to the intervention at admission and discharge from hospital. After 6 months after hospital discharge, patient's respiratory motion, lung function and disease specific health related quality of life will be evaluated. All outcomes will be described by mean (SD) or number (%). Independent t test or chi square test will be used to compare the basic data difference between training group and conventional group. Then, two-way analysis of variance or two-way analysis of covariance will be used to compare the outcomes difference between groups. Alpha level is set at 0.05.
OBJECTIVES: Comorbidities, as components of these heterogeneous features, often coexist with knee osteoarthritis, and are particularly prevalent in end-stage knee osteoarthritis. Here, we attempted to identify the different clinical phenotypes of comorbidities in patients with end-stage knee osteoarthritis by cluster analysis.
METHODS: A total of 421 inpatients diagnosed with end-stage knee osteoarthritis who underwent inpatient surgery were included in this cross-sectional study. 23 demographic, comorbidity, inflammatory immune and evaluation scale variables were collected. Systematic clustering after factor analysis and separate two-step cluster analysis were performed for individual comorbidity variables and all variables, respectively, to objectively identify the different clinical phenotypes of the study patients.
RESULTS: Four clusters were finally identified. Cluster 1 had the largest proportion of obese patients (93.8%) and hypertension was common (71.2%). Almost all patients in cluster 2 were depressed (95.8%) and anxiety disorders (94.7%). Cluster 3 combined patients with isolated end-stage knee osteoarthritis and a few comorbidities. Cluster 4 had the highest proportion of patients with rheumatoid arthritis (58.8%).
CONCLUSIONS: Patients with end-stage knee osteoarthritis may be classified into four different clinical phenotypes: "isolated end-stage knee osteoarthritis"; "obesity + hypertension"; "depression + anxiety"; and "rheumatoid arthritis", which may help guide individualized patient care and treatment strategies.
Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
A topical composition in sprayable form comprising (i) cornstarch, (ii) at least one antibiotic and/or (iii) clove oil. The cornstarch is in the form of granules that serve to form a microscopic scaffold and also provide nutrition and binding agent properties to damaged tissue. The preferred antibiotics are bacitracin, neomycin and polyrnixin B. All three of the above components can be used together to provide a pain relieving spray, which may take the form of a light emulsion. The composition may or may not be applied via an aerosol propellant. Finally, the composition may be used as a cellular building block tissue repair/cell therapy.
The naked mole-rat Heterocephalus glaber is a eusocial mammal exhibiting extreme longevity (37-year lifespan), extraordinary resistance to hypoxia and absence of cardiovascular disease. To identify the mechanisms behind these exceptional traits, metabolomics and RNAseq of cardiac tissue from naked mole-rats was compared to other African mole-rat genera (Cape, Cape dune, Common, Natal, Mahali, Highveld and Damaraland mole-rats) and evolutionarily divergent mammals (Hottentot golden mole and C57/BL6 mouse). We identify metabolic and genetic adaptations unique to naked mole-rats including elevated glycogen, thus enabling glycolytic ATP generation during cardiac ischemia. Elevated normoxic expression of HIF-1α is observed while downstream hypoxia responsive-genes are down-regulated, suggesting adaptation to low oxygen environments. Naked mole-rat hearts show reduced succinate levels during ischemia compared to C57/BL6 mouse and negligible tissue damage following ischemia-reperfusion injury. These evolutionary traits reflect adaptation to a unique hypoxic and eusocial lifestyle that collectively may contribute to their longevity and health span.
PROBLEM TO BE SOLVED: To enable a person in a distant place to accurately keep track of the daily health state of a managed person.SOLUTION: A sensor 2 is installed in a living room 300 in a residence 200 of a managed person 100, and outputs a detection signal corresponding to activities of the managed person 100 in the living room 300. A gateway device 3 is installed in the residence 200, and transmits data corresponding to the detection signal output by the sensor 2. A management device 4 is installed at a place distant from the residence 200, and receives the data transmitted by the gateway device 3. A terminal device 5 is able to communicate with the management device 4, and is able to present information to an observer 150 different from the managed person 100. An index generation unit 41 in the management device 4 stores the received data with time, and thereby generates an index corresponding to the state of the activities of the managed person 100 in the living room 300. A transmission unit 42 in the management device 4 transmits management information including the index to the terminal device 5.SELECTED DRAWING: Figure 1
<P>PROBLEM TO BE SOLVED: To provide a gelatin hard capsule having a high film strength, and to provide a method for producing the same.  <P>SOLUTION: This method for producing the gelatin hard capsule having a high film strength comprises processes comprising (i) adding 1 to 10 pts.wt. of a PEG mixture of PEG 600 and PEG 500 in a weight ratio of 40 to 60: 60 to 40 to a solution containing 100 pts.wt. of gelatin, (ii) adding 0.1 to 1.2 pts.wt. of a mixture of an emulsifier containing an acetyl glyceryl fatty acid ester and sodium lauryl sulfate to the mixture obtained above, and (iii) leaving the mixture obtained above, adjusting its viscosity, and forming the hard capsule from the same. The gelatin hard capsule of the present invention has a uniform film distribution minimizing cracks, even when a moisture-absorbing substance is inserted into the gelatin hard capsule.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
OBJECTIVE: In China, most of the patients who underwent kidney transplants have unknown causes of end-stage renal disease (uESRD). However, little is known regarding the incidence of graft glomerulonephritis (GN) and graft survival in kidney transplant recipients (KTRs) with uESRD.
METHODS: In this retrospective cohort study, 473 of the 565 KTRs who underwent kidney transplantation (KTx) from 2015 to 2020 were included. We mainly observed the occurrence of graft GN between uESRD group and definitively diagnosed GN group, and repeatedly compared after propensity score matching (PSM).
RESULTS: The median follow-up was 50 months in 473 KTRs, and about 75% of KTRs of native kidney disease of unknown etiology. The total cumulative incidence of graft GN was 17%, and no difference was observed between the definitively diagnosed GN group and the uESRD group (p = 0.76). Further, PSM analysis also showed no difference in the incidence of graft GN between the 2 groups. Multivariable analysis disclosed males (p = 0.001), younger age (p = 0.03), and anti-endothelial cell anti-body (AECA) positive pre-KTx (p = 0.001) were independent risk factors for graft GN.
CONCLUSIONS: The incidence of graft GN was similar between uESRD and definitively diagnosed GN group. The allograft survival was also similar between two groups.
Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.